Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: A 1-week, randomized, double-blind, placebo- and active-controlled study

Clinical Drug Investigation

Volumn 32, Issue 10, 2012, Pages 707-714

  Kay, Gary G ^a   Staskin, David R ^b   MacDiarmid, Scott ^c   McIlwain, Marilyn ^d   Dahl, Naomi V ^d  

^a Drug Development   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Alliance Urology Specialists   (United States)

^d Watson Laboratories Inc   (United States)

Author keywords

disorders cognition; Elderly; overactive bladder; oxybutynin gel; tolerability; topical

Indexed keywords

OXYBUTYNIN; PLACEBO;

ADULT; AGED; AGING; ANALYSIS OF VARIANCE; APTITUDE TEST; ARTICLE; COGNITION; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRY EYE; DRY NOSE; DRY THROAT; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LEARNING; MALE; MEMORY; MICTURITION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC EXAMINATION; NORMAL HUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RECALL; RESPONSE TIME; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; URINARY DYSFUNCTION; WORD RECOGNITION; XEROSTOMIA;

ADMINISTRATION, TOPICAL; AGED; ATTENTION; COGNITION; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; GELS; HUMANS; LEARNING; MALE; MANDELIC ACIDS; MEMORY; MENTAL RECALL; MIDDLE AGED; PARASYMPATHOLYTICS; PSYCHOMOTOR PERFORMANCE; REACTION TIME; URINARY BLADDER, OVERACTIVE;

EID: 84865486670     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11636310-000000000-00000     Document Type: Article

References (22)

1. Appell RA. Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent. Drugs 2006; 66 (10): 1361-70
2. Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003; 78: 696-702 (Pubitemid 36665899)
3. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997 Mar; 157 (3): 1093-7 (Pubitemid 27066324)
4. Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother 2009; 10 (18): 3103-11
5. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008; 62 (11): 1792-800
6. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 317-26 (Pubitemid 44038078)
7. Chapple CR. Muscarinic receptor antagonistsinthe treatment of overactive bladder. Urology 2000; 55 Suppl. 5A: 33-46
8. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006 (Pubitemid 47537675)
9. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166: 140-5 (Pubitemid 32565364)
10. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005; 23: 263-70
11. Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009 Apr; 181: 1764-72
12. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 Aug; 168 (2): 580-6 (Pubitemid 34793301)
13. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007; 99: 836-44 (Pubitemid 46439555)
14. Hughes KM, Lang JC, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992; 22 (7): 859-69
15. GELNIQUE (oxybutynin chloride) 10% gel [package insert]. Corona (CA): Watson Pharmaceuticals, Inc., Jan 2009
16. rd ed. New York (NY): Oxford University Press, 2009
17. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapyresearch. J Consult Clin Psychol 1991; 59 (1): 12-9
18. Sawrie SM, Chelune GJ, Luders HO. Empirical methods for assessing meaningful neuropsychological change following epilepsy surgery. JInt Neuropsychol Soc 1996; 2 (6): 556-64 (Pubitemid 126449822)
19. Diefenbach K, Arold G, Wollny A, et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ‡50 years. BJU Int 2005; 95: 346-9 (Pubitemid 40283121)
20. Kay G, Kardiasmenos K, Crook T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects [abstract no. 87]. Annual Meeting of the International Continence Society; 2006 Nov 27-Dec 1; Christchurch, New Zealand [online]. Available from URL: https://www.icsoffice.org/Abstracts/Publish/44/ 000087.pdf [Accessed 2012 Jan 11]
21. Zobrist RH, Schmid B, Feick A, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001; 18 (7): 1029-34 (Pubitemid 32799951)
22. Dmochowski RR, Newman DK, Sand PK, et al. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, showering, sunscreen, and person-to-person transference. Clin Drug Investig 2011; 31 (8): 559-71